Search

for
Search:

GlossaryNivolumab (Opdivo)

immunotherapy drug that helps immune system attack cancer cells

Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1 on the surface of T-cells, which helps the immune system recognize and attack cancer cells more effectively.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 10 results

research Eosinophilic Folliculitis of the Scalp Associated with PD-1/PDL1 Inhibitors

9 citations , April 2020 in “Journal of Cosmetic Dermatology”

Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.

research Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy

November 2022 in “Journal of the Endocrine Society”

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

research An Industry Update: What's New in the Field of Therapeutic Delivery This Month?

November 2016 in “Therapeutic Delivery”

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

research A Comparative Analysis of Immune Privilege in Pregnancy and Cancer in the Context of Checkpoint Blockade Immunotherapy

16 citations , March 2018 in “Seminars in Oncology”

The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.

research Cutaneous Manifestations Associated With Immune Checkpoint Inhibitors

14 citations , February 2023 in “Frontiers in immunology”

Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.

View more "opdivo" in research →

Community Join

0 / 0 results

— no results